 The offering raised gross proceeds of approximately 46 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. SunTrust Robinson Humphrey acted as a bookrunner for the offering. Marinus intends to use the net proceeds of the offering to fund the development of its product candidates and for general corporate purposes, which may include working capital, capital expenditures, research and development expenditures, clinical trial expenditures, acquisitions of new technologies, products or businesses, and investments. 